| name | malignancy-hypercalcemia-workup |
| description | Work up Malignancy-Associated Hypercalcemia (MAH) — distinguish humoral hypercalcemia of malignancy (HHM, PTHrP-driven), local osteolytic hypercalcemia, 1,25(OH)2D-mediated lymphoma hypercalcemia, ectopic PTH secretion, and multiple myeloma — and pick the right confirmatory tests and therapy direction. Trigger when a clinician asks "is this hypercalcemia from cancer", "PTHrP positive what now", "hypercalcemia in lung cancer / breast cancer / lymphoma / myeloma", "humoral hypercalcemia of malignancy", "MAH workup", or any hypercalcemia case with suppressed PTH and a known or suspected malignancy. |
Malignancy-Associated Hypercalcemia (MAH) — Workup
Use this skill when hypercalcemia is PTH-suppressed and malignancy is on the differential. MAH is usually acute, severe, and a marker of advanced disease.
STEP 1 — Confirm MAH vs. other PTH-independent causes
You should already have:
- Suppressed intact PTH
- Hypercalcemia (often >12 mg/dL with rapid onset)
- Suggestive setting (known cancer, weight loss, advanced disease, pathological fracture)
Order if not yet done:
- PTHrP
- 1,25(OH)2D and 25(OH)D
- SPEP + UPEP + serum free light chains
- CBC, peripheral smear, LDH
- Skeletal imaging — whole-body low-dose CT or PET-CT (more sensitive than bone scan, especially in myeloma)
- TSH, cortisol to exclude endocrine mimics
STEP 2 — Sub-classify MAH
Pattern A — Humoral Hypercalcemia of Malignancy (HHM) — PTHrP elevated, 1,25(OH)2D low/normal, often few or no bone metastases
Typical tumours:
- Squamous cell carcinoma: lung (most common), head & neck, oesophagus, cervix, vulva, skin
- Renal cell carcinoma
- Bladder, ovarian carcinoma
- Less commonly: colon, gastric, prostate, thyroid, non-squamous lung
Biochemistry: hypophosphatemia, low TmP/GFR, increased nephrogenous cAMP — mimics PTH action.
Action: search for the primary with imaging guided by symptoms (CT chest/abdomen/pelvis, ENT review for head & neck SCC, dermatologic exam, urine cytology). PTHrP can be tracked as a tumour marker once the diagnosis is established.
Pattern B — Solid tumour with skeletal metastases + elevated PTHrP (mixed mechanism)
Typical: breast cancer, prostate (rarely), other osteolytic mets.
Mechanism: PTHrP from tumour both raises systemic calcium and drives local osteolysis (RANKL ↑, OPG ↓, TGF-β feedback loop).
Action: confirm bone metastases (CT, bone scan, MRI as needed). Treat as MAH plus bone-targeted therapy.
Pattern C — Hematologic malignancy with elevated 1,25(OH)2D — lymphoma pattern
Typical: non-Hodgkin lymphoma, Hodgkin lymphoma.
Mechanism: extrarenal 1α-hydroxylase in tumour tissue. PTHrP may also be elevated in some cases.
Action: confirm lymphoma — LDH, lymph node biopsy, PET-CT, bone marrow if suspected. Glucocorticoids are particularly effective here (suppress 1α-hydroxylase + tumour activity).
Pattern D — Ectopic PTH secretion — PTH itself elevated (not PTHrP) in a non-parathyroid tumour
Rare. Documented tumours: ovarian, lung, thyroid, thymus, gastric.
Suspicion arises when imaging fails to identify a parathyroid adenoma despite biochemically PTH-dependent hypercalcemia. Confirm with tumour-tissue PTH immunostaining or molecular studies in selected cases.
Action: surgical removal of the primary if feasible.
Pattern E — Multiple myeloma — SPEP/UPEP positive, light chains elevated
Mechanism: bone-resorbing factors (MIP-1α, IL-6, RANKL ↑, OPG ↓, DKK-1, sclerostin). PTHrP rarely elevated.
Key clinical features:
- Hypercalcemia in ~30% of myeloma patients
- Often coexists with renal failure (Bence-Jones nephropathy, light-chain cast nephropathy) → so unlike other MAH, expect hyperphosphatemia, not hypophosphatemia
- ALP usually normal (no osteoblastic activity); bone scans frequently negative
- Bone pain in 80%, pathological fractures common
Action:
- Confirm: bone marrow biopsy, FISH (del17p, t(4;14), t(14;16), 1q gain, t(11;14)), whole-body low-dose CT or PET-CT.
- Bisphosphonates have a dual benefit — control hypercalcemia AND reduce skeletal events / tumour burden.
- See the mm-diagnostic-workup skill for the full myeloma workup.
STEP 3 — Decide treatment direction
Two parallel tracks:
Track 1 — Treat the hypercalcemia (use acute-hypercalcemia-management skill if Ca >12 with symptoms or >14):
- Hydration (NS), then antiresorptive (denosumab 120 mg SC, or zoledronic acid 4 mg IV, or pamidronate 60–90 mg IV).
- Glucocorticoids are particularly effective in lymphoma, myeloma, and granulomatous-pattern (1,25(OH)2D-driven) MAH.
- Calcitonin (4–8 IU/kg SC/IM q6–12h) for first 48–72 h while waiting for antiresorptive to take effect.
Track 2 — Treat the underlying cancer — definitive control of MAH requires reducing tumour burden. Without this, hypercalcemia recurs rapidly.
Track PTHrP after treatment:
- PTHrP does not fall with hypercalcemia treatment.
- PTHrP does fall with successful tumour reduction → useful as a tumour marker on follow-up.
CLINICAL GUARDRAILS
- MAH = advanced disease. Patients with new-onset MAH have a poor prognosis; involve oncology and palliative care early.
- Bone scan misses myeloma. Use whole-body low-dose CT or PET-CT.
- Hyperphosphatemia + hypercalcemia + suppressed PTH → think myeloma with renal failure, not HHM.
- Glucocorticoids are not first-line for HHM (they don't work) but ARE effective for lymphoma, myeloma, and granulomatous causes.
- Bisphosphonates need dose adjustment in renal impairment — denosumab is preferred when CrCl <30 mL/min (no renal clearance).
- Watch for hypocalcemia after antiresorptive in vitamin D-deficient patients — correct 25(OH)D first if low.
- PTHrP can be elevated in normocalcemic cancer patients — significance unclear; do not use in isolation to diagnose MAH.
SOURCE
Bilezikian JP, Endotext. Approach to Hypercalcemia. NCBI Bookshelf NBK279129. Section: Malignancy-Associated Hypercalcemia (HHM, MAH with skeletal metastases, hematologic malignancies, ectopic hyperparathyroidism, multiple myeloma).
